Klotho Neurosciences (NASDAQ:KLTO) Upgraded by Wall Street Zen to “Hold” Rating

Klotho Neurosciences (NASDAQ:KLTO) was upgraded by equities researchers at Wall Street Zen to a “hold” rating in a report released on Saturday.

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Klotho Neurosciences in a research report on Monday, December 29th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company currently has a consensus rating of “Sell”.

Klotho Neurosciences Stock Up 11.2%

NASDAQ:KLTO opened at $0.53 on Friday. The company has a market cap of $39.09 million, a P/E ratio of -1.66 and a beta of 10.27. The firm’s 50 day moving average is $0.31 and its two-hundred day moving average is $0.46. Klotho Neurosciences has a fifty-two week low of $0.11 and a fifty-two week high of $3.91.

Institutional Investors Weigh In On Klotho Neurosciences

A number of institutional investors have recently made changes to their positions in the company. Jane Street Group LLC bought a new position in Klotho Neurosciences during the second quarter worth $26,000. XTX Topco Ltd lifted its position in shares of Klotho Neurosciences by 101.2% in the 4th quarter. XTX Topco Ltd now owns 160,569 shares of the company’s stock worth $46,000 after buying an additional 80,768 shares during the last quarter. Renaissance Technologies LLC acquired a new position in shares of Klotho Neurosciences in the 4th quarter valued at about $126,000. Geode Capital Management LLC grew its position in shares of Klotho Neurosciences by 51.8% during the 4th quarter. Geode Capital Management LLC now owns 491,832 shares of the company’s stock valued at $142,000 after buying an additional 167,905 shares during the last quarter. Finally, Brummer Multi Strategy AB bought a new stake in shares of Klotho Neurosciences during the 4th quarter valued at about $175,000. 20.07% of the stock is currently owned by institutional investors.

About Klotho Neurosciences

Klotho Neurosciences, Inc, a biopharmaceutical company, develops therapies for neurological and age-related disorders, and specialty diagnostics. Its products include cell and gene therapies to mitigate age-related pathologies, such as dementia symptoms, and Alzheimer and neuromuscular diseases; biologics/biosimilars in the treatment of cancer; and melanocortin receptors. The company has a strategic partnership with Japan’s Okinawa Research Center for the research and development of Klotho gene therapy in enhancing longevity and reducing age-related diseases.